{"entity":{"id":"blacksmith-medicines","kind":"company","name":"Blacksmith Medicines","aka":["Blacksmith Medicines, Inc."],"tldr":"Blacksmith Medicines designs drugs against metal-containing enzymes. In cancer it is developing inhibitors of FEN1, a DNA-repair enzyme, to combine with PARP inhibitors in ovarian cancer, and the work is in the laboratory.","summary":"Blacksmith Medicines has a chemistry platform for medicines that target human metalloenzymes, with oncology and infectious disease programmes. In oncology it has developed non-hydroxyurea inhibitors of flap endonuclease 1 (FEN1), a DNA-repair metallonuclease with homologous recombination genes among its synthetic lethality partners, and lists QPCTL, which modifies CD47 and CCL2, as a myeloid immunotherapy target. In fiscal year 2026 NCI awarded it USD 399,915 under SBIR award 1R43CA309911-01A1 to combine a selective FEN1 inhibitor with olaparib in PARP inhibitor-resistant ovarian cancer.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://blacksmithmedicines.com/"},{"label":"Blacksmith Medicines: pipeline and targets","url":"https://blacksmithmedicines.com/pipeline-targets/"},{"label":"NIH RePORTER: SBIR award 1R43CA309911-01A1","url":"https://reporter.nih.gov/project-details/11410176"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["targeted-therapy","drug-discovery"],"technologies":["synthetic-lethality-approaches","parp-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No named oncology compound on the company website. Read on blacksmithmedicines.com and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"San Diego, CA","country":"US","companyType":"biotech","website":"https://blacksmithmedicines.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":399915,"source":"https://reporter.nih.gov/project-details/11410176","note":"NCI SBIR award (R43) 1R43CA309911-01A1: Combination of a novel selective FEN1 metallonuclease inhibitor with Olaparib for the treatment of PARP-resistant ovarian cancers"}]},"route":"/companies/blacksmith-medicines/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}]}}